Franklin Resources
ARQT icon

Franklin Resources’s Arcutis Biotherapeutics ARQT Stock Holding History

Franklin Resources’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.6M Sell
1,930,982
-366,961
-16% -$8.55M 0.01% 676
2026
Q1 		$54.1M Buy
2,297,943
+397,859
+21% +$10.2M 0.01% 624
2025
Q4 		$55.2M Sell
1,900,084
-410,935
-18% -$10.5M 0.01% 608
2025
Q3 		$43.6M Sell
2,311,019
-421,758
-15% -$6.65M 0.01% 691
2025
Q2 		$38.3M Sell
2,732,777
-28,990
-1% -$406K 0.01% 712
2025
Q1 		$43.2M Sell
2,761,767
-547,552
-17% -$7.71M 0.01% 653
2024
Q4 		$46.1M Sell
3,309,319
-941,099
-22% -$10.3M 0.01% 642
2024
Q3 		$41.4M Sell
4,250,418
-187,761
-4% -$1.85M 0.01% 666
2024
Q2 		$41.3M Sell
4,438,179
-204,281
-4% -$1.85M 0.01% 606
2024
Q1 		$46M Sell
4,642,460
-13,084
-0.3% -$97.7K 0.01% 595
2023
Q4 		$15M Buy
4,655,544
+3,363,191
+260% +$9.14M 0.01% 826
2023
Q3 		$6.86M Sell
1,292,353
-360,183
-22% -$3.06M ﹤0.01% 997
2023
Q2 		$15.7M Buy
1,652,536
+59,166
+4% +$657K 0.01% 831
2023
Q1 		$17.5M Buy
1,593,370
+795,634
+100% +$11.5M 0.01% 809
2022
Q4 		$11.8M Sell
797,736
-1,260
-0.2% -$22K 0.01% 903
2022
Q3 		$15.3M Buy
798,996
+5,100
+0.6% +$116K 0.01% 841
2022
Q2 		$16.9M Buy
793,896
+134,060
+20% +$2.75M 0.01% 830
2022
Q1 		$12.7M Buy
659,836
+44,091
+7% +$746K 0.01% 955
2021
Q4 		$12.8M Buy
615,745
+40,537
+7% +$807K ﹤0.01% 990
2021
Q3 		$13.7M Sell
575,208
-520
-0.1% -$11.9K 0.01% 987
2021
Q2 		$15.7M Sell
575,728
-77,280
-12% -$2.18M 0.01% 922
2021
Q1 		$18.9M Buy
+653,008
New +$20.4M 0.01% 849

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Franklin Resources's ARQT Position: Q2 2026 in Review

Franklin Resources reduced its Arcutis Biotherapeutics (ARQT) stake by 16% in Q2 2026, selling an estimated $8.55M and leaving 1,930,982 shares worth $50.6M. The position accounts for 0.01% of the portfolio, ranked #676.

Franklin Resources first reported a position in ARQT in Q1 2021 and has held it in 22 quarters since. The position peaked at $55.2M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Franklin Resources held 1,930,982 shares of Arcutis Biotherapeutics worth $50.6M as of Q2 2026.
  • Franklin Resources sold 366,961 Arcutis Biotherapeutics shares in Q2 2026, an estimated $8.55M.
  • Arcutis Biotherapeutics made up 0.01% of Franklin Resources's portfolio in Q2 2026, its #676 holding.
  • Franklin Resources first reported a position in Arcutis Biotherapeutics in Q1 2021 and has held it in 22 quarters since.
  • Franklin Resources's Arcutis Biotherapeutics position peaked at $55.2M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.